Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114256 · ClinicalTrials.gov registry record
FNA Tumor Sampling for CD137 Modulation: A Pilot Study
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 83
- Enrollment target
NCT01114256: Clinical Trial study, sponsored by Stanford University.
NCT01114256 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01114256 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand the biology of the body's immune response to monoclonal antibody therapy for cancer. Your health information will be used to identify your tissues. The tissue we obtain may be useful for research or education, resulting in new drugs, therapies or diagnostic procedures.
Interventions
- PROCEDURE FNA Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2010-03 |
| Est. Completion | 2016-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01114256
The ClinicalTrials.gov registry entry for NCT01114256 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FNA Biopsy is the first listed.
NCT01114256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01114256 about?
NCT01114256 is a clinical study titled "FNA Tumor Sampling for CD137 Modulation: A Pilot Study". The purpose of this study is to better understand the biology of the body's immune response to monoclonal antibody therapy for cancer. Your health information will be used to identify your tissues. The tissue we obtain may be useful for research or education, resulting in new drugs, therapies or dia...
What is the current status of trial NCT01114256?
This trial is currently terminated. The enrollment target is 83 participants. The study started on 2010-03. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01114256?
The interventions under investigation include: FNA Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT01114256?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.